Showing results (211-220 of 239) with videos related to
Sort By:
Pageof 24
Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.Cancer Immunology Research|January 11, 2022
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in MelanomaMaryam Pourmaleki, Caitlin J Jones, Charlotte E Ariyan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.Pageof 24